combination therapy

John Gribben’s ASH 2019 CLL and lymphoma highlights

Promising venetoclax updates in AML: DEC10-VEN, CLAD/LDAC, antifungals

Marina Konopleva

Developing mantle cell lymphoma treatment for further success

Update on selinexor for myeloma and large cell lymphomas

MRD in the immuno-chemo era

Florence Cymbalista

MURANO: outcomes after the end of treatment

CLL treatment: statistical analysis in predictive medicine

Comparing CLL regimens with MRD

Predicting suboptimal response through intermediate MRD

Andrew Rawstron

Novel combination therapies in CLL

Will cellular therapy have a role in CLL in 2020?

Venetoclax phase III trial disappointment

Jarrod Longcor: ESMO highlights

Proof of principle to progress treatments

Myeloma tackling combinations

Will knowledge of the molecular pathology of lymphoma improve clinical trials?

David Maloney et al.

1
2
3
4
5
…
22
Next